<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01275469</url>
  </required_header>
  <id_info>
    <org_study_id>GFT505-209-4</org_study_id>
    <secondary_id>2009-011003-23</secondary_id>
    <nct_id>NCT01275469</nct_id>
  </id_info>
  <brief_title>Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.</brief_title>
  <official_title>A Pilot Study to Evaluate the Efficacy and Safety of GFT505 (80 mg) Orally Administered Once Daily for 35 Days in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity. A Double Blind, Parallel Group, Placebo-controlled and Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genfit</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genfit</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of GFT505 80mg compared with placebo in
      improving Oral Glucose Tolerance Test (OGTT), in patients with impaired glucose tolerance and
      abdominal obesity, and to assess the tolerability and safety of once-a-day administrations of
      oral doses of GFT505 during 35 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study period is 13 weeks maximum per patient : A screening period (1 to 6-weeks) will
      precede a 5-week double-blind treatment period and a 2-week follow-up period. The duration of
      the screening period will depend on the necessity to introduce a wash-out for lipid-lowering
      drugs : 4-week wash-out from statins and other lipid regulating drugs and 6-week wash-out
      from fibrates. During the screening period, patients will be asked to start or continue
      adequate diet and exercise.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oral Glucose test Tolerance (OGTT)</measure>
    <time_frame>4 weeks</time_frame>
    <description>To evaluate the change in plasma Glucose 2hr following oral glucose load from baseline to end point. Evaluation will be made during the selection period, prior any drug intake, and 4 weeks (28-34 days) after the first treatment intake.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume oxygen maximal (VO2max)</measure>
    <time_frame>5 weeks</time_frame>
    <description>To evaluate the efficacy of GFT505 80mg compared with placebo in improving the VO2max at physical exercise test. Evaluation will be made during the selection period, prior any drug intake, and 5 weeks after the first treatment intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory parameters measured during the physical exercise test</measure>
    <time_frame>5 weeks</time_frame>
    <description>To describe the changes on others parameters measured during the physical exercise test : Volume carbon dioxide (VCO2), Respiratory quotient (RQ), Lactate concentration. Evaluation will be made during the selection period, prior any drug intake, and 5 weeks after the first treatment intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Glycemia and Insulinemia</measure>
    <time_frame>5 weeks</time_frame>
    <description>To describe the changes of fasting glycaemia and insulinemia in the two groups. Evaluation will be made the first day prior any drug intake, then 5 weeks after the first treatment intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA index (Homeostasis Model Assessment)</measure>
    <time_frame>5 weeks</time_frame>
    <description>To describe the changes of HOMA index in the two groups. Evaluation will be made the first day prior any drug intake, then 5 weeks after the first treatment intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids</measure>
    <time_frame>5 weeks</time_frame>
    <description>To describe the changes in Triglycerides (TG), High Density Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein Cholesterol (LDL-C) and non High Density Lipoprotein Cholesterol (non-HDL-C) levels in the two groups. Evaluation will be made the first day prior any drug intake, then 2-3, and 4 weeks after the first treatment intake and 2 weeks after the last treatment intake (follow-up visit).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Impaired Glucose Tolerance</condition>
  <condition>Abdominal Obesity</condition>
  <arm_group>
    <arm_group_label>GFT505 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFT505 80mg</intervention_name>
    <description>Hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast.</description>
    <arm_group_label>GFT505 80mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Hard gelatin capsules, oral administration, 4 capsules per day before breakfast.</description>
    <arm_group_label>Matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or post-menopausal female.

          -  Waist circumference ≥94cm for male, ≥ 80cm for female.

          -  Fasting Plasma Glucose (FPG) between 110 and 126 mg/dl (between 6.1 and 7.0 mmol/l)
             within 6 months prior to the screening visit.

          -  2-hour glycaemia at OGTT (2hr after a 75g oral glucose load) ≥140 mg/dL (7.8 mmol/l).

        Exclusion Criteria:

          -  Body Mass Index (BMI) ≥ 40 kg/m².

          -  Blood Pressure &gt; 160 / 95 mmHg.

          -  Known Type I or type II Diabetes Mellitus.

          -  Glycated haemoglobin (HbA1c) &gt;7%.

          -  A fasting TG &gt; 400mg/dl and a LDL-C &gt; 220mg/dl.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rémy Hanf, Development Director</last_name>
    <role>Study Director</role>
    <affiliation>GENFIT, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric BRUCKERT, Pr.</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of Paris 6, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site n°31</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°32</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°36</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°37</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°34</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°35</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°39</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°17</name>
      <address>
        <city>Briollay</city>
        <zip>49125</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°16</name>
      <address>
        <city>Cholet</city>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°19</name>
      <address>
        <city>Cholet</city>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°14</name>
      <address>
        <city>le MESNIL en VALLEE</city>
        <zip>49410</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°10</name>
      <address>
        <city>Murs-erigne</city>
        <zip>49610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°12</name>
      <address>
        <city>Murs-erigne</city>
        <zip>49610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°2</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°13</name>
      <address>
        <city>Parcay Les Pins</city>
        <zip>49390</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°1</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°15</name>
      <address>
        <city>Segre</city>
        <zip>49500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°11</name>
      <address>
        <city>Thouars</city>
        <zip>79100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°30</name>
      <address>
        <city>Tierce</city>
        <zip>49125</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°18</name>
      <address>
        <city>Vihiers</city>
        <zip>49310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2011</study_first_submitted>
  <study_first_submitted_qc>January 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2011</study_first_posted>
  <last_update_submitted>January 11, 2011</last_update_submitted>
  <last_update_submitted_qc>January 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Product Development Department</name_title>
    <organization>GENFIT</organization>
  </responsible_party>
  <keyword>Impaired Glucose tolerance</keyword>
  <keyword>OGTT</keyword>
  <keyword>PPARs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Obesity, Abdominal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

